52/73
  • Pages
  • Editions
01 Cover
02 Welcome Letter / Sections
03 Article & Interview Directory
04 Section 1: Introduction
05 Introduction to US Life Sciences
06 Janssen Pharmaceuticals Interview
07 Investment Climate
08 MPM Capital Interview
09 Signet Healthcare Partners Interview
10 Xontogeny Interview
11 Insights from EisnerAmper
12 The Life Sciences Regulatory Climate
13 Buchanan Ingersoll & Rooney PC Interview
14 PhRMA Interview
15 PBOA Interview
16 Ernst & Young LLP Interview
17 LaVoieHealthScience Interview
18 Section 2: Introducing the Hubs
19 East Coast
20 BioNJ Interview
21 MassBio Interview
22 Pennsylvania Biotechnology Center Interview
23 West Coast
24 Biocom California Interview
25 QB3-Berkeley Interview
26 Section 3: Drug Discovery and Development
27 Therapeutic Fields On Fire
28 Insmed Interview
29 Mammoth Biosciences Interview
30 Innovations Enhancing the Patient Experience
31 Arcturus Therapeutics Interview
32 Karius Interview
33 Expert Insights: Targeted Therapeutics
34 First Wave BioPharma Interview
35 Aphios Corporation Interview
36 Section 4: Contract Manufacturing and Chemicals
37 A Shifting Landscape
38 Syngene International Interview
39 Cambrex Interview
40 Lubrizol Life Science Interview
41 Aenova Group Interview
42 Keeping Up With Demands
43 Cureline Interview
44 Interview: Murli Krishna Pharma
45 PsychoGenics Interview
46 Expert Insights: Innovative Technologies
47 AMPAC Fine Chemicals Interview
48 TCG Lifesciences Interview
49 CordenPharma Interview
50 Quotient Sciences Interview
51 A Post-Pandemic World
52 New Vision Pharmaceuticals Interview
53 Adare Pharma Solutions Interview
54 Ascendia Pharmaceuticals Interview
55 Chemicals Producers and Distributors
56 Brenntag North America Interview
57 BASF Pharma Solutions Interview
58 Section 5: Technology Services
59 Life Sciences Go Digital
60 RxS Interview
61 Insights from Markem-Imaje
62 AiCure Interview
63 WhizAI Interview
64 Section 6: Company Profiles
65 Brenntag Company Profile
66 Adare Pharma Solutions Company Profile
67 Quotient Sciences Company Profile
68 SK pharmteco Company Profile
69 AiCure Company Profile
70 Markem-Imaje Company Profile
71 TCG Lifesciences Company Profile
72 Murli Krishna Pharma Company Profile
73 Credits

Alan Petro, CEO,

NEW VISION PHARMACEUTICALS

"We had a client approach us to work on a rapid Covid test, wanting to produce a single-use vial for at-home testing. It was only six weeks between when we had our initial discussion to when we had produced the product for them."

What were the highlights of 2021 for New Vision Pharmaceuticals (New Vision), and what have the impacts of the pandemic been on the company’s operations?

New Vision Pharmaceuticals was fortunate to have experienced significant growth in 2021. We have been developing relationships with mid-tier and large organizations for both tech transfer developments and fill-finish operations. We are also supporting significant OTC production for private label and branded products.

Given the supply chain issues that arose from Covid, there has been a strong push to shorten supply chains. New Vision has been particularly responsive to our clients' needs in this regard and we have been able to significantly shorten our supply chains, especially compared to products produced overseas. For example, we had a client approach us to work on a rapid Covid test, wanting to produce a single-use vial for at-home testing. It was only six weeks between when we had our initial discussion to when we had produced the product for them. We quickly made many millions of vials to support the rapid ramp-up. If they had attempted to do this with an offshore supplier, it would have taken the same amount of time just to get the product across the ocean and through ports. This level of responsiveness has been our focus.

Can you elaborate on this desire from clients to reshore their manufacturing capabilities?

We have observed an enormous effort to reshore manufacturing capacity, particularly as a result of limited transport capacity coupled with the congestion in US ports, which has consequences not only from a timeline perspective but also for bottom line financials. The cost to transport a container has increased four-fold, making it a serious factor to consider. Additionally, geopolitical turmoil such as the crisis unfolding in Ukraine is pushing many organizations to question the value of a far-flung global supply network.

What are some of the benefits you see in blow-fill-seal (BFS) as a manufacturing process?

The idea behind single-use vials is that the patient consumes all the contents. Often, people have medicine cabinets filled with expired products. With single-use vials, on the other hand, you purchase in smaller quantities and consume fully. BFS also makes products incredibly difficult to counterfeit, which is a serious issue on a global scale. This way, the purchaser has assurance that what they think they are purchasing is what they actually get.

What trends have you observed in the adoption of BFS in the US?

Some of the early adopters of BFS technology in the US have been hospitals, nursing homes and other large care facilities. From a medication control standpoint, these products are easier to measure and leave no waste left in the bottle. Additionally, we are seeing strong demand from the pediatric market. It is easier for a mother to carry various single-use, non-breakable vials rather than lugging around several bottles.

Additionally, the need for at-home Covid tests is increasing significantly, which seems to be an outcome of the lockdown period. People need medical care irrespective of the challenges they face in physically going to a hospital or clinician. Being able to receive a test through the mail that you can do at home represents the future of medicine in broader terms as well. A major shortcoming of the American medical delivery system is that while there is an availability of physicians in major metropolitan areas, there is a severe lack in more remote locations. We see a significant opportunity for telemedicine and at-home testing services to support the needs of these populations.

How will New Vision grow over the next few years to continue to meet the demands of its clients?

New Vision will continue to focus on sterile and nonsterile pharmaceuticals, with our primary markets being ophthalmic, respiratory, and dermatological. We are also seeking partnerships to utilize our large open clean room capacity. Additionally, the company will increase its product development teams to be able to work with a number of different clients that may have great ideas but not know how to bring them to the marketplace. This is where New Vision truly has the potential to make an impact.

Next:

Interview: Adare Pharma Solutions